ribavirin has been researched along with Hypoxia in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (20.00) | 18.2507 |
| 2000's | 1 (20.00) | 29.6817 |
| 2010's | 1 (20.00) | 24.3611 |
| 2020's | 2 (40.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cheng, GS; Kicska, GA; Kinahan, PE; Li, T; Liu, L; Pipavath, SNJ; Wu, W | 1 |
| Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S | 1 |
| Brock, E; Doern, C; Pugni, L; Ronchi, A; Sánchez, PJ | 1 |
| Buttrey, MJ; Chiou, HE; Kuo, HP; Kuo, HT; Liu, CL; Liu, HW; Lu, YT | 1 |
| Snell, NJ | 1 |
2 review(s) available for ribavirin and Hypoxia
| Article | Year |
|---|---|
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral Agents; Arrhythmias, Cardiac; Chloroquine; COVID-19 Drug Treatment; Drug Combinations; Drug Interactions; Electrocardiography; Heart Failure; Humans; Hydroxychloroquine; Hypoxia; Inflammation; Long QT Syndrome; Lopinavir; Myocarditis; Myocardium; Precipitating Factors; Receptors, Interleukin-6; Respiratory Distress Syndrome; Ribavirin; Ritonavir; SARS-CoV-2; Water-Electrolyte Imbalance | 2021 |
Neonatal adenoviral infection: a seventeen year experience and review of the literature.
Topics: Adenoviridae; Adenoviridae Infections; Age Factors; Antiviral Agents; Body Temperature; Cidofovir; Cohort Studies; Cough; Cytosine; Diarrhea; Fatigue; Female; Gastrointestinal Hemorrhage; Hepatomegaly; Humans; Hypotension; Hypoxia; Immunoglobulins, Intravenous; Infant, Newborn; Intensive Care Units, Neonatal; Irritable Mood; Male; Muscle Hypotonia; Organophosphonates; Pancytopenia; Polymerase Chain Reaction; Respiratory Sounds; Retrospective Studies; Ribavirin; Splenomegaly; Tachypnea; Vomiting | 2014 |
3 other study(ies) available for ribavirin and Hypoxia
| Article | Year |
|---|---|
The novel coronavirus disease (COVID-19) complicated by pulmonary embolism and acute respiratory distress syndrome.
Topics: Acute Disease; Aged; Biomarkers; Blood Platelets; Ceftazidime; COVID-19; COVID-19 Drug Treatment; Dyspnea; Fibrin Fibrinogen Degradation Products; Heparin; Humans; Hypoxia; Lung; Male; Methylprednisolone; Middle Aged; Pulmonary Embolism; Respiratory Distress Syndrome; Ribavirin; SARS-CoV-2; Tomography, X-Ray Computed; Treatment Outcome | 2020 |
Adverse effects of ribavirin and outcome in severe acute respiratory syndrome: experience in two medical centers.
Topics: Adult; Anemia; Antiviral Agents; Chi-Square Distribution; Communicable Diseases, Emerging; Female; Humans; Hypoxia; Logistic Models; Male; Middle Aged; Retrospective Studies; Ribavirin; Risk Factors; Severe Acute Respiratory Syndrome; Statistics, Nonparametric; Taiwan; Treatment Outcome | 2005 |
Idiosyncratic reaction to nebulised ribavirin.
Topics: Administration, Inhalation; Bronchial Spasm; Humans; Hypoxia; Infant, Newborn; Ribavirin; Ribonucleosides; Risk Factors | 1990 |